Optimizing denileukin diftitox (Ontak) therapy
- PMID: 18684057
- DOI: 10.2217/14796694.4.4.457
Optimizing denileukin diftitox (Ontak) therapy
Abstract
Denileukin diftitox (Ontak) is a novel recombinant fusion protein consisting of peptide sequences for the enzymatically active and membrane translocation domain of diphtheria toxin linked to human IL-2. Denileukin diftitox specifically binds to IL-2 receptors on the cell membrane, is internalized via receptor-mediated endocytosis and inhibits protein synthesis by ADP ribosylation of elongation factor 2, resulting in cell death. This article focuses on the clinical trial that led to the US FDA approval of the drug for cutaneous T-cell lymphoma in 1999, and other investigational studies for hematologic malignancies, recurrent and refractory chronic lymphocytic leukemia, non-Hodgkin B-cell lymphoma, graft-versus-host disease and autoimmune disease, demonstrating the activity and adverse effects of the drug.
Similar articles
-
Clinical experience with denileukin diftitox (ONTAK).Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. doi: 10.1053/j.seminoncol.2005.12.017. Semin Oncol. 2006. PMID: 16516670 Review.
-
Denileukin diftitox: a concise clinical review.Expert Rev Anticancer Ther. 2005 Feb;5(1):33-8. doi: 10.1586/14737140.5.1.33. Expert Rev Anticancer Ther. 2005. PMID: 15757436 Review.
-
Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. doi: 10.1586/14737140.7.1.11. Expert Rev Anticancer Ther. 2007. PMID: 17187516 Review.
-
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.Am J Hematol. 2008 Jul;83(7):593-5. doi: 10.1002/ajh.21180. Am J Hematol. 2008. PMID: 18335564
-
Denileukin diftitox.Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. doi: 10.2165/00128071-200001010-00008. Am J Clin Dermatol. 2000. PMID: 11702307 Review.
Cited by
-
Cellular Entry of the Diphtheria Toxin Does Not Require the Formation of the Open-Channel State by Its Translocation Domain.Toxins (Basel). 2017 Sep 22;9(10):299. doi: 10.3390/toxins9100299. Toxins (Basel). 2017. PMID: 28937631 Free PMC article.
-
Plant Toxic Proteins: Their Biological Activities, Mechanism of Action and Removal Strategies.Toxins (Basel). 2023 May 24;15(6):356. doi: 10.3390/toxins15060356. Toxins (Basel). 2023. PMID: 37368657 Free PMC article. Review.
-
Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox.JAAD Case Rep. 2017 Oct 25;3(6):501-504. doi: 10.1016/j.jdcr.2017.06.031. eCollection 2017 Nov. JAAD Case Rep. 2017. PMID: 29296637 Free PMC article. No abstract available.
-
The role of protein synthesis in cell cycling and cancer.Mol Oncol. 2009 Dec;3(5-6):402-8. doi: 10.1016/j.molonc.2009.05.003. Epub 2009 Jun 11. Mol Oncol. 2009. PMID: 19546037 Free PMC article. Review.
-
Biologics in dermatologic therapy - an update.Indian J Dermatol. 2009 Jul;54(3):211-20. doi: 10.4103/0019-5154.55627. Indian J Dermatol. 2009. PMID: 20161849 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
